Selling to medical device makers

Medical device companies live inside a quality system. Every design change, supplier change and software update has to be documented, tested and defensible to a regulator.

That makes them careful buyers. It doesn't make them slow ones. When a rule changes or a recall lands, they need help fast, and they pay for people who already speak the language.

Sell them speed with no risk to compliance and you'll get a meeting. Sell them speed at the cost of compliance and you won't get a second one.

What's changing

Quality rules are converging. The FDA's updated quality system regulation took effect in early 2026 and brings US requirements much closer to ISO 13485. Companies are rewriting procedures, retraining staff and checking whether their systems hold up.

Products are becoming software. Insulin pumps, monitors, imaging systems and implants now connect to apps and clouds. That brings cyber requirements into premarket submissions and a steady stream of software updates after launch.

Europe is still hard. The EU's device regulation raised the bar on clinical evidence and technical files, and many companies are still working through the backlog for older products.

And portfolios keep moving. Large device makers buy smaller ones for their technology and spin off businesses that don't fit. Every deal leaves quality systems, ERP and product data to merge or separate.

Who buys

The head of quality and regulatory affairs has more power here than in most industries. They can stop a project that puts a submission or an audit at risk. Treat them as a buyer, not a checkpoint.

The COO or head of operations owns manufacturing, supply chain and the cost of goods. They buy plant, supplier and planning work.

The CTO or head of R&D owns product development, including the software inside the device. For connected products, a head of digital health or software engineering often runs the program.

The CIO owns the ERP, the quality management system and the product lifecycle tools. Many device makers run these as separate systems that barely talk.

The CFO signs off on anything large, and gets pulled in hard after a recall.

The signals that matter most

FDA actions are the strongest signal. A warning letter, a Form 483 after an inspection or a recall puts a deadline on remediation work. Warning letters are public, and they read like a scope of work. A consent order comes with a deadline covers the timing logic.

Regulatory changes set the calendar for the whole industry. A new rule effective date tells you when quality teams will be stretched thin.

Acquisitions are reliable. A device maker buying a smaller company has to bring its products into one quality system before the next audit.

Hiring is specific. Posts for quality systems engineers, software validation leads or medical device cybersecurity engineers name the program.

And product launches matter. A connected device clearance usually means a cloud platform, a support model and post-market monitoring that all need to be built.

An example opener

Say Halvern Medical receives an FDA warning letter citing gaps in its complaint handling and corrective action process. The letter is posted publicly. A new VP of quality joined from a larger device maker two months earlier.

The warning letter Halvern received last month calls out complaint handling and the corrective action process, and you walked into it two months into the role. The FDA will want a credible plan with dates, and your team is still running the old procedures day to day. My guess is the bigger gap is the data between complaints, service records and CAPA, not the procedures themselves. Is that accurate, or is the bigger issue something else?

Every fact is public. The trigger is personal and recent. And the guess points at a systems problem a quality leader might not have time to fix alone.

What to avoid

Don't treat devices like pharma. The rules, the products and the buyers differ, with the same regulator over both. If you sell into both, see selling to life sciences companies.

Don't make compliance claims you can't back. Saying your work is FDA-ready means nothing. Show how your team handles validation and documentation.

Don't pitch innovation to a company in remediation. After a warning letter, the only priority is closing it.

And don't leave quality out of the first conversation. If they hear about you late, they'll assume you'll create work for them.

The point

Device makers buy when a regulator, a recall or a deal puts a date on the calendar. Read the public record, write to the person holding the deadline and respect the quality system. For more on timing, see regulatory change as a buying signal.